nach oben

Neurosurgical Review

Erschienen in:

17.02.2018 | Review

Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma

verfasst von: Meric A. Altinoz, Aysel Ozpinar, Ilhan Elmaci

Erschienen in: Neurosurgical Review | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Female gender, contraceptives, and menopausal hormone replacement treatments containing progesterone analogues associate with higher risk of meningiomas yet with lower risk of gliomas. Progesterone receptor (PR) expression and mifepristone treatment was highly discussed for meningiomas. However, much less is known in regard to progesterone actions in gliomas despite PR expression strongly correlates with their grade. Meningiomas and gliomas may grow faster during gestation; but paradoxically, parousity reduces lifetime risk of gliomas which can be explained with dichotomous cell growth-stimulating and inhibitory actions of progesterone at low versus high levels. Progesterone levels gradually increase in gestation up to 200-fold and the incidence of highly angiogenic brain tumors decreases in the last trimester. Indeed, progesterone stimulates glial tumor cell growth at low doses (10 nM) while induces cell kill at higher doses. During gestation, some immune pathways are activated to protect the mother and the fetus against microbial pathogens. In parallel, high-dose medroxyprogesterone acetate (MPA) used in treatment of endometrial carcinoma decreases tumoral expression of PR-B and increases infiltration of cytotoxic T lymphocytes and natural killer cells. MPA also synergies with IL-2 in clinical treatment of renal cancer. In both glioma and meningioma, the dominant cytosolic PR is PR-B which increases cell growth, while PR-A limits cell growth. This seems also paradoxical at the first glance due to opposite behavior of these tumors in diverse endocrine conditions. High-dose progestins may inhibit brain tumor growth by downregulating PR-B, yet the dosage thresholds may differ between glial and meningeal tumors due to higher total PR expression in meningiomas. Supporting this proposal, certain progestins were reported to stimulate meningioma growth in anecdotal reports, but same agents at much higher doses reduced meningioma cell proliferation in pilot clinical studies. PR antagonist mifepristone reduced meningioma growth in some clinical studies, but lacked efficacy in others. In fact, mifepristone also has partial PR agonist efficacy and acts in synergy with MPA to block EC growth. Hence, a similar mechanism of receptor downregulation may also account for mifepristone. Both MPA and mifepristone also harbor myeloprotective features against chemotherapy. Ulipristal is another contraceptive PR antagonist and exerts promising anticancer activity on drug-resistant ovarian cancer and BRCA1-mutant breast cancer cells, which can be tested in animal glioblastoma models. We propose that progestins strongly deserve to be investigated in experimental models of glioblastoma alone and in combination with immunostimulating agents.

Abulafia O, Triest WE, Adcock JT, Sherer DM (1999) The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia. Gynecol Oncol 72(2):193–198. https://doi.org/10.1006/gyno.1998.5106 CrossRefPubMed

Ackerman WE 4th, Summerfield TL, Mesiano S, Schatz F, Lockwood CJ, Kniss DA (2016) Agonist-dependent downregulation of progesterone receptors in human cervical stromal fibroblasts. Reprod Sci 23(1):112–123. https://doi.org/10.1177/1933719115597787 CrossRefPubMed

Altinoz MA, Bilir A, Gedikoglu G, Ozcan E, Oktem G, Muslumanoglu M (2007a) Medroxyprogesterone and tamoxifen augment anti-proliferative efficacy and reduce mitochondria-toxicity of epirubicin in FM3A tumor cells in vitro. Cell Biol Int 31(5):473–481. https://doi.org/10.1016/j.cellbi.2006.11.013 CrossRefPubMed

Altinoz MA, Bilir A, Ozar E, Onar FD, Sav A (2001a) Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro. Int J Dev Neurosci 19(6):541–547. https://doi.org/10.1016/S0736-5748(01)00045-4 CrossRefPubMed

Altinoz MA, Gedikoglu G, Sav A, Ozcan E, Ozdilli K, Bilir A, Del Maestro RF (2007b) Medroxyprogesterone acetate induces c6 glioma chemosensitization via antidepressant-like lysosomal phospholipidosis/myelinosis in vitro. Int J Neurosci 117(10):1465–1480. https://doi.org/10.1080/00207450701540062 CrossRefPubMed

Andersen L, Friis S, Hallas J, Ravn P, Gaist D (2013) Hormone replacement therapy and risk of glioma: a nationwide nested case-control study. Cancer Epidemiol 37(6):876–880. https://doi.org/10.1016/j.canep.2013.09.017 CrossRefPubMed

Andersen L, Friis S, Hallas J, Ravn P, Kristensen BW, Gaist D (2015) Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study. Br J Clin Pharmacol 79(4):677–684. https://doi.org/10.1111/bcp.12535 CrossRefPubMed

Anic GM, Madden MH, Nabors LB, Olson JJ, LaRocca RV, Thompson ZJ, Pamnani SJ, Forsyth PA, Thompson RC, Egan KM (2014) Reproductive factors and risk of primary brain tumors in women. J Neuro-Oncol 118(2):297–304. https://doi.org/10.1007/s11060-014-1427-0 CrossRef

Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Varakis J (1998) Does sex steroid receptor status have any prognostic or predictive significance in brain astrocytic tumors? Clin Neuropathol 17(1):27–34PubMed

10.

Atif F, Sayeed I, Yousuf S, Ishrat T, Hua F, Wang J, Brat DJ, Stein DG (2011) Progesterone inhibits the growth of human neuroblastoma: in vitro and in vivo evidence. Mol Med 17(9–10):1084–1094. https://doi.org/10.2119/molmed.2010.00255 CrossRefPubMedPubMedCentral

11.

Atif F, Patel NR, Yousuf S, Stein DG (2015a) The synergistic effect of combination progesterone and temozolomide on human glioblastoma cells. PLoS One 10(6):e0131441. https://doi.org/10.1371/journal.pone.0131441 CrossRefPubMedPubMedCentral

12.

Atif F, Yousuf S, Stein DG (2015b) Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling. J Steroid Biochem Mol Biol 146:62–73. https://doi.org/10.1016/j.jsbmb.2014.04.007 CrossRefPubMed

13.

Attardi BJ, Burgenson J, Hild SA, Reel JR (2004) In vitro antiprogestational/ antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol 88(3):277–288. https://doi.org/10.1016/j.jsbmb.2003.12.004 CrossRefPubMed

14.

Bazer FW, Burghardt RC, Johnson GA, Spencer TE, Wu G (2008) Interferons and progesterone for establishment and maintenance of pregnancy: interactions among novel cell signaling pathways. Reprod Biol 8(3):179–211. https://doi.org/10.1016/S1642-431X(12)60012-6 CrossRefPubMed

15.

Benakanakere I, Besch-Williford C, Schnell J, Brandt S, Ellersieck MR, Molinolo A, Hyder SM (2006) Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clin Cancer Res 12(13):4062–4071. https://doi.org/10.1158/1078-0432.CCR-06-0427 CrossRefPubMed

16.

Benson VS, Pirie K, Green J, Bull D, Casabonne D, Reeves GK, Beral V (2010) Million women study collaborators. Hormone replacement therapy and incidence of central nervous system tumours in the million women study. Int J Cancer 127(7):1692–1698. https://doi.org/10.1002/ijc.25184 CrossRefPubMed

17.

Benson VS, Kirichek O, Beral V, Green J (2015) Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 136(10):2369–2377. https://doi.org/10.1002/ijc.29274 CrossRefPubMed

18.

Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA (2006) Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res 66(12):6421–6431. https://doi.org/10.1158/0008-5472.CAN-05-4235 CrossRefPubMed

19.

Bouchard P (2011) Current and future medical treatments for menometrorrhagia during the premenopause. Gynecol Endocrinol 27(Suppl 1):1120–1125. https://doi.org/10.3109/09513590.2012.638754 CrossRefPubMed

20.

Cabrera-Muñoz E, González-Arenas A, Saqui-Salces M, Camacho J, Larrea F, García-Becerra R, Camacho-Arroyo I (2009) Regulation of progesterone receptor isoforms content in human astrocytoma cell lines. J Steroid Biochem Mol Biol 113(1–2):80–84. https://doi.org/10.1016/j.jsbmb.2008.11.009 CrossRefPubMed

21.

Cantor KP, Lynch CF, Johnson D (1993) Reproductive factors and risk of brain, colon, and other malignancies in Iowa (United States). Cancer Causes Control 4(6):505–511. https://doi.org/10.1007/BF00052425 CrossRefPubMed

22.

Carroll RS, Zhang J, Dashner K, Sar M, Black PM (1995) Steroid hormone receptors in astrocytic neoplasms. Neurosurgery 37(3):496–503. https://doi.org/10.1227/00006123-199509000-00019 CrossRefPubMed

23.

Chakravarty PK, Ghosh SK, Sinha DK (1991) Pregnancy-induced cytotoxicity of splenocytes against mammary tumor cells in rats. Oncology 48(5):425–430. https://doi.org/10.1159/000226973 CrossRefPubMed

24.

Clarke RB, Howell A, Anderson E (1997) Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat 45(2):121–133. https://doi.org/10.1023/A:1005805831460 CrossRefPubMed

25.

Classen S, Possinger K, Pelka-Fleischer R, Wilmanns W (1993) Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol 45(4):315–319. https://doi.org/10.1016/0960-0760(93)90348-Z CrossRefPubMed

26.

Classen-Linke I, Alfer J, Hey S, Krusche CA, Kusche M, Beier HM (1998) Marker molecules of human endometrial differentiation can be hormonally regulated under in-vitro conditions as in-vivo. Hum Reprod Update 4(5):539–549. https://doi.org/10.1093/humupd/4.5.539 CrossRefPubMed

27.

Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Le Guillou M, Perrault de Jotemps M, Chauvet MP, Chaouat M, Pujol P, Feunteun J, Delaloge S, Forgez P, Gompel A (2016) Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations. Oncotarget 7(29):45317–45330. https://doi.org/10.18632/oncotarget.9638 CrossRefPubMedPubMedCentral

28.

Concolino G, Liccardo G, Conti C, Panfili C, Giuffre R (1984) Hormones and tumours in central nervous system (CNS): steroid receptors in primary spinal cord tumours. Neurol Res 6(3):121–126. https://doi.org/10.1080/01616412.1984.11739676 CrossRefPubMed

29.

Cork DM, Lennard TW, Tyson-Capper AJ (2008) Alternative splicing and the progesterone receptor in breast cancer. Breast Cancer Res 10(3):207. https://doi.org/10.1186/bcr2097 CrossRefPubMedPubMedCentral

30.

Couzinet B, Schaison G (1988) Mifegyne (mifepristone), a new antiprogestagen with potential therapeutic use in human fertility control. Drugs 35(3):187–191. https://doi.org/10.2165/00003495-198835030-00001 CrossRefPubMed

31.

Cowppli-Bony A, Bouvier G, Rué M, Loiseau H, Vital A, Lebailly P, Fabbro-Peray P, Baldi I (2011) Brain tumors and hormonal factors: review of the epidemiological literature. Cancer Causes Control 22(5):697–714. https://doi.org/10.1007/s10552-011-9742-7 CrossRefPubMed

32.

Daniel AR, Knutson TP, Lange CA (2009) Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol 308(1–2):47–52. https://doi.org/10.1016/j.mce.2009.01.004 CrossRefPubMedPubMedCentral

33.

Dragoman MV, Gaffield ME (2016) The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): a systematic review. Contraception 94(3):202–215. https://doi.org/10.1016/j.contraception.2016.02.003 CrossRefPubMed

34.

D'Souza AW, Wagner GP (2014) Malignant cancer and invasive placentation: a case for positive pleiotropy between endometrial and malignancy phenotypes. Evol Med Public Health 2014(1):136–145. https://doi.org/10.1093/emph/eou022 CrossRefPubMedPubMedCentral

35.

Elmaci İ, Altinoz MA, Sav A, Yazici Z, Ozpinar A (2016) Giving another chance to mifepristone in pharmacotherapy for aggressive meningiomas—a likely synergism with hydroxyurea? Curr Probl Cancer 40(5–6):229–243. https://doi.org/10.1016/j.currproblcancer.2016.05.001 CrossRefPubMed

36.

Esber N, Le Billan F, Resche-Rigon M, Loosfelt H, Lombès M, Chabbert-Buffet N (2015) Ulipristal acetate inhibits progesterone receptor isoform A-mediated human breast cancer proliferation and BCl2-L1 expression. PLoS One 10(10):e0140795. https://doi.org/10.1371/journal.pone.0140795 CrossRefPubMedPubMedCentral

37.

Felini MJ, Olshan AF, Schroeder JC, Carozza SE, Miike R, Rice T, Wrensch M (2009) Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control 20(1):87–96. https://doi.org/10.1007/s10552-008-9220-z CrossRefPubMed

38.

Focan C, Beauduin M, Salamon E, de Greve J, de Wasch G, Lobelle JP, Majois F, Tagnon A, Tytgat J, van Belle S, Vandervellen R, Vindevoghel A, Adjuvant Breast Cancer Project Belgium (2001) Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. Br J Cancer 85(1):1–8. https://doi.org/10.1054/bjoc.2001.1829 CrossRefPubMedPubMedCentral

39.

Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR (2009) Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol 25(12):807–815. https://doi.org/10.3109/09513590903056878 CrossRefPubMed

40.

Gamarra-Luques CD, Hapon MB, Goyeneche AA, Telleria CM (2014) Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity. J Ovarian Res 7(1):45. https://doi.org/10.1186/1757-2215-7-45 CrossRefPubMedPubMedCentral

41.

Gatchev O, Råstam L, Lindberg G, Gullberg B, Törnberg S, Eklund GA (1994) Tumours of the central nervous system and concentration of total serum cholesterol and beta-lipoprotein in men and women. Br J Cancer 70(4):668–671. https://doi.org/10.1038/bjc.1994.368 CrossRefPubMedPubMedCentral

42.

Georgakulias N, Singounas E, Kypriades E, Giotis J, Karvounis P (1993) Estrogen and progesterone receptors in meningiomas and gliomas. Zentralbl Neurochir 54(3):139–142PubMed

43.

Germán-Castelán L, Manjarrez-Marmolejo J, González-Arenas A, Camacho-Arroyo I (2016) Intracellular progesterone receptor mediates the increase in glioblastoma growth induced by progesterone in the rat brain. Arch Med Res 47(6):419–426. https://doi.org/10.1016/j.arcmed.2016.10.002 CrossRefPubMed

44.

Germán-Castelán L, Manjarrez-Marmolejo J, González-Arenas A, González-Morán MG, Camacho-Arroyo I (2014) Progesterone induces the growth and infiltration of human astrocytoma cells implanted in the cerebral cortex of the rat. Biomed Res Int 2014:393174–393178. https://doi.org/10.1155/2014/393174 CrossRefPubMedPubMedCentral

45.

Gleicher N, Siegel I (1981) Common denominators of pregnancy and malignancy. Prog Clin Biol Res 70:339–353PubMed

46.

González-Agüero G, Gutiérrez AA, González-Espinosa D, Solano JD, Morales R, González-Arenas A, Cabrera-Muñoz E, Camacho-Arroyo I (2007) Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines. Endocrine 32(2):129–135. https://doi.org/10.1007/s12020-007-9023-0 CrossRefPubMed

47.

González-Agüero G, Ondarza R, Gamboa-Domínguez A, Cerbón MA, Camacho-Arroyo I (2001) Progesterone receptor isoforms expression pattern in human astrocytomas. Brain Res Bull 56(1):43–48. https://doi.org/10.1016/S0361-9230(01)00590-1 CrossRefPubMed

48.

González-Arenas A, Valadez-Cosmes P, Jiménez-Arellano C, López-Sánchez M, Camacho-Arroyo I (2014) Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway. J Steroid Biochem Mol Biol 144 Pt B:463–470. https://doi.org/10.1016/j.jsbmb.2014.09.007 CrossRefPubMed

49.

Goyeneche AA, Seidel EE, Telleria CM (2012) Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Investig New Drugs 30(3):967–980. https://doi.org/10.1007/s10637-011-9655-z CrossRef

50.

Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB (1997) Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 11(11):1593–1607. https://doi.org/10.1210/mend.11.11.0006 CrossRefPubMed

51.

Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S (1999) Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci U S A 96(5):2520–2525. https://doi.org/10.1073/pnas.96.5.2520 CrossRefPubMedPubMedCentral

52.

Günzel-Apel A, Urhausen C, Wolf K, Einspanier A, Oei C, Piechotta M (2012) Serum progesterone in pregnant bitches supplemented with progestin because of expected or suspected luteal insufficiency. Reprod Domest Anim 47(Suppl 6):55–60. https://doi.org/10.1111/rda.12029 CrossRefPubMed

53.

Haas JF (1984) Pregnancy in association with a newly diagnosed cancer: a population-based epidemiologic assessment. Int J Cancer 34(2):229–235. https://doi.org/10.1002/ijc.2910340214 CrossRefPubMed

54.

Haas JF, Jänisch W, Staneczek W (1986) Newly diagnosed primary intracranial neoplasms in pregnant women: a population-based assessment. J Neurol Neurosurg Psychiatry 49(8):874–880. https://doi.org/10.1136/jnnp.49.8.874 CrossRefPubMedPubMedCentral

55.

Hagan CR, Lange CA (2014) Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med 12(1):32. https://doi.org/10.1186/1741-7015-12-32 CrossRefPubMedPubMedCentral

56.

Hatch EE, Linet MS, Zhang J, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD (2005) Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 114(5):797–805. https://doi.org/10.1002/ijc.20776 CrossRefPubMed

57.

Hensiek AE, Kellerman AJ, Hill JT (2000) Spontaneous regression of a solitary cerebral metastases in renal carcinoma followed by meningioma development under medroxyprogesterone acetate therapy. Br J Neurosurg 14(4):354–356CrossRefPubMed

58.

Hernández-Hernández OT, González-García TK, Camacho-Arroyo I (2012) Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines. J Steroid Biochem Mol Biol 132(1–2):127–134. https://doi.org/10.1016/j.jsbmb.2012.04.005 CrossRefPubMed

59.

Hernández-Hernández OT, Rodríguez-Dorantes M, González-Arenas A, Camacho-Arroyo I (2010) Progesterone and estradiol effects on SRC-1 and SRC-3 expression in human astrocytoma cell lines. Endocrine 37(1):194–200. https://doi.org/10.1007/s12020-009-9288-6 CrossRefPubMed

60.

Hild SA, Reel JR, Hoffman LH, Blye RP (2000) CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod 15(4):822–829. https://doi.org/10.1093/humrep/15.4.822 CrossRefPubMed

61.

Hlavaty J, Ertl R, Miller I, Gabriel C (2016) Expression of progesterone receptor membrane component 1 (PGRMC1), progestin and adipoQ receptor 7 (PAQPR7), and plasminogen activator inhibitor 1 RNA-binding protein (PAIRBP1) in glioma spheroids in vitro. Biomed Res Int 2016:8065830–8065812. https://doi.org/10.1155/2016/8065830 CrossRefPubMedPubMedCentral

62.

Huang K, Whelan EA, Ruder AM, Ward EM, Deddens JA, Davis-King KE et al (2004) Reproductive factors and risk of glioma in women. Cancer Epidemiol Biomark Prev 13(10):1583–1588

63.

Hudon V, Berthod F, Black AF, Damour O, Germain L, Auger FA (2003) A tissue-engineered endothelialized dermis to study the modulation of angiogenic and angiostatic molecules on capillary-like tube formation in vitro. Br J Dermatol 148(6):1094–1104. https://doi.org/10.1046/j.1365-2133.2003.05298.x CrossRefPubMed

64.

İnce B, Guloksuz S, Altınbaş K, Oral ET, Alpkan LR, Altinoz MA (2013) Minor hemoglobins HbA2 and HbF associate with disease severity in bipolar disorder with a likely protective role of HbA2 against post-partum episodes. J Affect Disord 151(1):405–408. https://doi.org/10.1016/j.jad.2013.06.042 CrossRefPubMed

65.

Inoue T, Akahira J, Suzuki T, Darnel AD, Kaneko C, Takahashi K, Hatori M, Shirane R, Kumabe T, Kurokawa Y, Satomi S, Sasano H (2002) Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab 87(11):5325–5331. https://doi.org/10.1210/jc.2002-012096 CrossRefPubMed

66.

Jääskeläinen J, Laasonen E, Kärkkäinen J, Haltia M, Troupp H (1986) Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir 80(1–2):35–41. https://doi.org/10.1007/BF01809555 CrossRefPubMed

67.

Kabat GC, Etgen AM, Rohan TE (2010) Do steroid hormones play a role in the etiology of glioma? Cancer Epidemiol Biomark Prev 19(10):2421–2427. https://doi.org/10.1158/1055-9965.EPI-10-0658 CrossRef

68.

Kabat GC, Park Y, Hollenbeck AR, Schatzkin A, Rohan TE (2011) Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP diet and health study. Int J Cancer 128(4):944–950. https://doi.org/10.1002/ijc.25413 CrossRefPubMedPubMedCentral

69.

Khalid H, Shibata S, Kishikawa M, Yasunaga A, Iseki M, Hiura T (1997) Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors. Cancer 80(11):2133–2140. https://doi.org/10.1002/(SICI)1097-0142(19971201)80:11<2133::AID-CNCR13>3.0.CO;2-#

70.

Koyama H (1999) Adjuvant therapy with high-dose medroxyprogesterone acetate for operable breast cancer. Breast Cancer 6(2):99–107. https://doi.org/10.1007/BF02966915 CrossRefPubMed

71.

Krishnamachari B, Il’yasova D, Scheurer ME, Bondy ML, Wrensch M, Davis FG (2014) A pooled multisite analysis of the effects of female reproductive hormones on glioma risk. Cancer Causes Control 25(8):1007–1013. https://doi.org/10.1007/s10552-014-0400-8 CrossRefPubMedPubMedCentral

72.

Kuhl H, Schneider HP (2013) Progesterone—promoter or inhibitor of breast cancer. Climacteric 16(Suppl 1):54–68. https://doi.org/10.3109/13697137.2013.768806 CrossRefPubMed

73.

Lambe M, Coogan P, Baron J (1997) Reproductive factors and the risk of brain tumors: a population-based study in Sweden. Int J Cancer 72(3):389–393. https://doi.org/10.1002/(SICI)1097-0215(19970729)72:3<389::AID-IJC2>3.0.CO;2-L CrossRefPubMed

74.

Lange CA, Richer JK, Horwitz KB (1999) Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13(6):829–836. https://doi.org/10.1210/mend.13.6.0290 CrossRefPubMed

75.

Lee O, Choi MR, Christov K, Ivancic D, Khan SA (2016) Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation. Cancer Lett 376(2):310–317. https://doi.org/10.1016/j.canlet.2016.04.010 CrossRefPubMed

76.

Lissoni P, Barni S, Tancini G, Brivio F, Cardellini P, Vaghi M, Fossati V, Frigerio F (1993) Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy. Tumori 79(4):246–249CrossRefPubMed

77.

Liu L, Shi G, Zhang Y, Lai Y, Liu Y, Lu X (2010) Effects of medroxyprogesterone acetate on endothelial progenitor cell. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 27(6):1317–1321PubMed

78.

Magrassi L, Butti G, Silini E, Bono F, Paoletti P, Milanesi G (1993) The expression of genes of the steroid-thyroid hormone receptor superfamily in central nervous system tumors. Anticancer Res 13(4):859–866PubMed

79.

Markwalder TM, Gerber HA, Waelti E, Schaffner T, Markwalder RV (1988) Hormonotherapy of meningiomas with medroxyprogesterone acetate. Immunohistochemical demonstration of the effect of medroxyprogesterone acetate on growth fractions of meningioma cells using the monoclonal antibody Ki-67. Surg Neurol 30(2):97–101. https://doi.org/10.1016/0090-3019(88)90093-6 CrossRefPubMed

80.

Markwalder TM, Waelti E, König MP (1987) Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on receptor status of meningioma cytosols. Surg Neurol 28(1):3–9. https://doi.org/10.1016/0090-3019(87)90198-4 CrossRefPubMed

81.

Martinoli C, Zocchi E, Querzola F, Damiani G, Zaccheo D (1984) Progesterone enhances reactive oxygen intermediates production by cultured human monocytes. Boll Soc Ital Biol Sper 60(10):1871–1877PubMed

82.

Melcangi RC, Cavarretta I, Magnaghi V, Ballabio M, Martini L, Motta M (1998) Crosstalk between normal and tumoral brain cells. Effect on sex steroid metabolism. Endocrine 8(1):65–71. https://doi.org/10.1385/ENDO:8:1:65 CrossRefPubMed

83.

Meyer ME, Pornon A, Ji JW, Bocquel MT, Chambon P, Gronemeyer H (1990) Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J 9(12):3923–3932CrossRefPubMedPubMedCentral

84.

Misra Y, Bentley PA, Bond JP, Tighe S, Hunter T, Zhao FQ (2012) Mammary gland morphological and gene expression changes underlying pregnancy protection of breast cancer tumorigenesis. Physiol Genomics 44(1):76–88. https://doi.org/10.1152/physiolgenomics.00056.2011 CrossRefPubMed

85.

Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G (2009a) Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res 29(4):1047–1052PubMed

86.

Moe BG, Vereide AB, Orbo A, Sager G (2009b) High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. Anticancer Res 29(4):1053–1058PubMed

87.

Naglieri E, Lopez M, Lelli G, Morelli F, Amodio A, Di Tonno P, Gebbia N, Di Seri M, Chetri MC, Rizzo P, Abbate I, Casamassima A, Selvaggi FP, Colucci G (2002) Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Res 22(5):3045–3051PubMed

88.

Obr AE, Edwards DP (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357(1–2):4–17. https://doi.org/10.1016/j.mce.2011.10.030 CrossRefPubMed

89.

Osorio Y, Bonilla DL, Peniche AG, Melby PC, Travi BL (2008) Pregnancy enhances the innate immune response in experimental cutaneous leishmaniasis through hormone-modulated nitric oxide production. J Leukoc Biol 83(6):1413–1422. https://doi.org/10.1189/jlb.0207130 CrossRefPubMed

90.

Paoletti P, Butti G, Zibera C, Scerrati M, Gibelli N, Roselli R, Magrassi L, Sica G, Rossi G, Robustelli della Cuna G (1990) Characteristics and biological role of steroid hormone receptors in neuroepithelial tumors. J Neurosurg 73(5):736–742. https://doi.org/10.3171/jns.1990.73.5.0736 CrossRefPubMed

91.

Piña-Medina AG, Hansberg-Pastor V, González-Arenas A, Cerbón M, Camacho-Arroyo I (2016) Progesterone promotes cell migration, invasion and cofilin activation in human astrocytoma cells. Steroids 105:19–25. https://doi.org/10.1016/j.steroids.2015.11.008 CrossRefPubMed

92.

Plunkett RJ, Lis A, Barone TA, Fronckowiak MD, Greenberg SJ (1999) Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg 90(6):1072–1077. https://doi.org/10.3171/jns.1999.90.6.1072 CrossRefPubMed

93.

Poisson M, Pertuiset BF, Hauw JJ, Philippon J, Buge A, Moguilewsky M, Philibert D (1983) Steroid hormone receptors in human meningiomas, gliomas and brain metastases. J Neuro-Oncol 1(3):179–189. https://doi.org/10.1007/BF00165601 CrossRef

94.

Purmonen S, Manninen T, Pennanen P, Ylikomi T (2008) Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep 19(6):1627–1634PubMed

95.

Qi ZY, Shao C, Zhang X, Hui GZ, Wang Z (2013) Exogenous and endogenous hormones in relation to glioma in women: a meta-analysis of 11 case-control studies. PLoS One 8(7):e68695. https://doi.org/10.1371/journal.pone.0068695 CrossRefPubMedPubMedCentral

96.

Rao BR (1997) Pregnancy associated highly vascularized tumours negatively correlate with the levels of anti-angiogenic 17 alpha-hydroxy-progesterone. Anticancer Res 17(2A):1019–1021PubMed

97.

Reel JR, Hild-Petito S, Blye RP (1998) Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats. Contraception 58(2):129–136. https://doi.org/10.1016/S0010-7824(98)00067-5 CrossRefPubMed

98.

Riva M, Sterzi R, Canepari C, Erminio F, Bizzozzero L (1990) Prognostic relevance of hormonal and kinetic parameters in CNS neoplasms. J Neurosurg Sci 34(3–4):227–230PubMed

99.

Roelvink NC, Kamphorst W, van Alphen HA, Rao BR (1987) Pregnancy-related primary brain and spinal tumors. Arch Neurol 44(2):209–215. https://doi.org/10.1001/archneur.1987.00520140069020 CrossRefPubMed

100.

Rosenthal M (1977) Enhanced phagocytosis of immune complexes in pregnancy. Clin Exp Immunol 28(1):189–191PubMedPubMedCentral

101.

Sartor O, Cutler GB Jr (1996) Mifepristone: treatment of Cushing’s syndrome. Clin Obstet Gynecol 39(2):506–510. https://doi.org/10.1097/00003081-199606000-00024 CrossRefPubMed

102.

Scarpin KM, Graham JD, Mote PA, Clarke CL (2009) Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal 7:e009. https://doi.org/10.1621/nrs.07009 CrossRefPubMedPubMedCentral

103.

Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A (1999) Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 82(2):155–160. https://doi.org/10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.0.CO;2-P CrossRefPubMed

104.

Shao R (2013) Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma. Ecancermedicalscience 7:381. https://doi.org/10.3332/ecancer.2013.381 CrossRefPubMedPubMedCentral

105.

Shinomiya N, Tsuru S, Taniguchi M, Fujisawa H, Ikeda M, Zinnaka Y, Nomoto K (1986) Immune protective mechanisms during pregnancy. I. Cell-mediated immunity against Listeria monocytogenes in pregnant mice. Immunology 59(3):373–378PubMedPubMedCentral

106.

Sica G, Zibera C, Ranelletti FO, Scerrati M, Butti G, Roselli R, Rossi GF, Robustelli Della Cuna G (1989) Some differences in steroid receptors between meningeal and neuroepithelial tumors. J Neurosurg Sci 33(1):71–75PubMed

107.

Silvera SA, Miller AB, Rohan TE (2006) Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer 118(5):1321–1324. https://doi.org/10.1002/ijc.21467 CrossRefPubMed

108.

Sitruk-Ware R (2006) Mifepristone and misoprostol sequential regimen side effects, complications and safety. Contraception 74(1):48–55. https://doi.org/10.1016/j.contraception.2006.03.016 CrossRefPubMed

109.

Snow SE, Melillo SN, Jarvis CI (2011) Ulipristal acetate for emergency contraception. Ann Pharmacother 45(6):780–786. https://doi.org/10.1345/aph.1P704 CrossRefPubMed

110.

Sood AK, Fletcher MS, Hendrix MJ (2002) The embryonic-like properties of aggressive human tumor cells. J Soc Gynecol Investig 9(1):2–9. https://doi.org/10.1177/107155760200900102 CrossRefPubMed

111.

Stratton P, Hartog B, Hajizadeh N, Piquion J, Sutherland D, Merino M, Lee YJ, Nieman LK (2000) A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 15(5):1092–1099. https://doi.org/10.1093/humrep/15.5.1092 CrossRefPubMed

112.

Tseng L, Zhu HH (1997) Regulation of progesterone receptor messenger ribonucleic acid by progestin in human endometrial stromal cells. Biol Reprod 57(6):1360–1366. https://doi.org/10.1095/biolreprod57.6.1360 CrossRefPubMed

113.

Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB (1993) Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7(10):1256–1265. https://doi.org/10.1210/mend.7.10.8123133 CrossRefPubMed

114.

Utsunomiya H, Suzuki T, Ito K, Moriya T, Konno R, Sato S, Yaegashi N, Okamura K, Sasano H (2003) The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. Clin Endocrinol 58(6):696–703. https://doi.org/10.1046/j.1365-2265.2003.01766.x CrossRef

115.

Vadivelu S, Sharer L, Schulder M (2010) Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg 112(5):920–924. https://doi.org/10.3171/2009.8.JNS09201 CrossRefPubMed

116.

van den Berg HW, Lynch M, Martin JH (1993) The relationship between affinity of progestins and antiprogestins for the progesterone receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: evidence for heterospecific receptor modulation via the glucocorticoid receptor. Eur J Cancer 29A(12):1771–1775CrossRefPubMed

117.

von Schoultz E, Bixo M, Bäckström T, Silfvenius H, Wilking N, Henriksson R (1990) Sex steroids in human brain tumors and breast cancer. Cancer 65(4):949–952. https://doi.org/10.1002/1097-0142(19900215)65:4<949::AID-CNCR2820650421>3.0.CO;2-2 CrossRef

118.

Waelti ER, Markwalder TM (1989) Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture. Surg Neurol 31(2):96–100. https://doi.org/10.1016/0090-3019(89)90318-2 CrossRefPubMed

119.

Weidenfeld J, Schiller H (1984) Metabolism of steroids by human brain tumors. Clin Neuropharmacol 7(4):395–397. https://doi.org/10.1097/00002826-198412000-00021 CrossRefPubMed

120.

Werner A, Aichberger A, Krebs D (1996) Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells? Zentralbl Gynakol 118(11):616–621PubMed

121.

Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164(7):629–636. https://doi.org/10.1093/aje/kwj254 CrossRefPubMed

122.

Witkiewicz AK, McConnell T, Potoczek M, Emmons RV, Kurman RJ (2010) Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Hum Pathol 41(1):26–32. https://doi.org/10.1016/j.humpath.2009.06.012 CrossRefPubMed

123.

Zaino RJ, Brady WE, Todd W, Leslie K, Fischer EG, Horowitz NS, Mannel RS, Walker JL, Ivanovic M, Duska LR (2014) Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol 33(6):543–553. https://doi.org/10.1097/PGP.0000000000000177 CrossRefPubMedPubMedCentral

Titel: Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma
verfasst von: Meric A. Altinoz
Aysel Ozpinar
Ilhan Elmaci
Publikationsdatum: 17.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Neurosurgical Review / Ausgabe 2/2019
Print ISSN: 0344-5607
Elektronische ISSN: 1437-2320
DOI: https://doi.org/10.1007/s10143-018-0953-1

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma

Abstract

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

Fehlerkultur in der Medizin – Offenheit zählt!

Mehr Frauen im OP – weniger postoperative Komplikationen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Pseudarthrosis in adult and pediatric spinal deformity surgery: a systematic review of the literature and meta-analysis of incidence, characteristics, and risk factors

Two-level cervical corpectomy—long-term follow-up reveals the high rate of material failure in patients, who received an anterior approach only

Rate and risk factors for a hyperactivity delirium in patients with aneurysmal subarachnoid haemorrhage

What is the best therapeutic approach to a pediatric patient with a deep-seated brain AVM?

Deep brain stimulation of the anterior nucleus of the thalamus for drug-resistant epilepsy

Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta-analysis of randomized controlled trials

Update Chirurgie